Beijing Biostar clarifies HK$ 4 subscription price, corrects agreement date to May 6

• Beijing Biostar Pharmaceuticals issued a clarification on its planned subscription of new shares under a general mandate, confirming the subscription agreement was dated May 6, not May 7.
• Subscription price set at HKD 4 per share, representing an 11.11% discount to the HKD 4.5 closing price on May 6, or a 10.11% discount to the five-day average closing price of HKD 4.45.
• Long stop date corrected to the 20th business day after the June 26 AGM, or about July 24, replacing an earlier reference to one month after the agreement date.
• New shares slated to be issued under the general mandate expected to be granted at the June 26 AGM, with no separate shareholder approval required.
• Proceeds earmarked mainly for ADC research and development, oncology commercialization efforts for Utidelone products, new innovation project sourcing, and general working capital.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beijing Biostar Pharmaceuticals Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260521-12167367), on May 21, 2026, and is solely responsible for the information contained therein.